☄️Late breakingTRAIL1 RCT Pirfenidone on RA-ILD. ✨Primary outcome on incidence of decline of >10% FVC or death not met 11% PIR vs. 15% PBO OR=0.67 p=0.48 BUT ✨underpowered ✨reduces decline in FVC(ml) over 52wk (-66 vs. -146, p=0.0082) ✨safety ok #ACR21 #AbstL10 @RheumNow https://t.co/IxYDE3lN1s

Safety update for #filgotinib in #RA over ~2.2yrs treatment 👉🏼Well-tolerated with no ne safety concerns since 2020 👉🏼AE incidence rates decreased or remained stable 👉🏼Slight incr rates of NMSC & non-NMSC malignancies Abs#1698 #ACR21 @RheumNow https://t.co/0jbZFVgiyN https://t.co/yOlntLwQlU

• Integrated Safety Analysis Update for Filgotinib in Patients with Moderately to…

#ACR21 Ab#1655. Respiratory Ifn in RA on bDMARD ▶️1 group was initiated into vaccination program vs usual care ⭐️Vaccinated group had ⬇️ admissions from respiratory ifns. 44% ⬇️ severe resp ifn 💉programs work! @Rheumnow https://t.co/pljR6DbAtU https://t.co/goSHGID8qG

• https://bit.ly/3F3JkzH

Isolated axial involvement exists in 2-5% of PsA patients. In 576 patients 495 (31.4%) had axial disease, of which 32 (2.0%) had isolated axial disease. HLA-B*27+ and lower HAQ scores were associated with isolated axial disease @RheumNow #ACR21 Abst#1775 https://t.co/Y1EAJlA0mT https://t.co/8oZhN3mT30

• Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis - A…

In this study: 💊No correlation bet QTc interval & whole blood HCQ level regardless of dose, CKD or abnormal TTEs in #lupus pts 💊+correlation bet QTci & HCQ levels in pts w/ QTc prolonging drugs but not >456ms Reassuring, dispels concern on HCQ use @RheumNow #ACR21 abs1743 https://t.co/kpASRAXJB1

#Multimorbidity in women with #rheumatoidarthritis is increased compared to men with RA. However, women and men without RA have similar levels of multimorbidity. Abs#1656 #ACR21 @RheumNow https://t.co/iXhXOldTy0 https://t.co/CsOM7odE69

• Women with Rheumatoid Arthritis Have More Multimorbidity Than Men in a Large Na…

#ACR21 Ab#1658 - Autoimmune Risks in Relatives of RA pts. 1st degree relatives have risk of: ▶️ AI thyroid (OR 1.3) ▶️ Celiac (1.5) ▶️ SLE (1.3) ▶️ IBD - no ⬆️ risk ⭐️1st, 2nd, 3rd degree relativ: ⬆️ risk of RA ⭐️2nd degree: ⬆️ risk SLE https://t.co/ATHdemoF45 @Rheumnow #ACRbest https://t.co/JcuZmg9L8E

• https://bit.ly/3GZjEGd

GLORIA RCT: 400+ pts. Low dose Pred in RA >65yo on top of other treatments 2yrs. Authors conclude benefit/risk balance in favour of GCs 🧐 2 thoughts: 1️⃣ CV risk linked to GCs ⬆️ over time and cumulative dose: Follow up= short! 2️⃣ Small # for CV events #ACR21 #Abst 1678 @RheumNow https://t.co/QECJR68ZJu

Dr Deike on prevalence and incidence of PsA in Germany. Prevalence 5-6/1000. Incidence 30-40/100000. Marked age variations that don't really make sense for prevalence. Abstr#1785 #ACR21 @RheumNow https://t.co/uW0ruW2Jda

What is the likelihood of developing an #autoimmunedisease in first-degree relatives of pts with #RA? Genealogical & phenotypic data suggests lower threshold for screening for autoimmune thyroiditis, #coeliac & #SLE in FDRs. Abs#1658 #ACR21 @RheumNow https://t.co/PdSZ05elsf https://t.co/AkIXDkWCM8

• Risk of Other Autoimmune Conditions Among Relatives of Patients with Rheumatoid…

#ACR21 Ab#L02 - #COVID19 vax in rheumatic pts: ❌No ⬆️ in disease activity scores post-vaccination ❌No serious adverse event ▶️Vax response 88% in RA, 78% in SLE, 87% other rheum diseases after 2 shots vs 100% controls ⭐️RTX and MMF ⬇️ responses @Rheumnow https://t.co/BChhmW0jpy https://t.co/2q8IKRoYqW

• https://bit.ly/3kkT94g

Dr Hebing on s/c vs oral methotrexate. erythrocyte methotrexate polyglutamates significantly higher with s/c administration. s/c consistently seems to be the better option, better efficacy, less side effects. Abstr#1695 #ACR21 @RheumNow https://t.co/kLGr6pVnxQ

Can we predict which PsO pts will develop PsA? Machine learning and phenotyping of blood immune cell subsets identified an immune profile to discriminate PsO from PsA. Abs#1774 #ACR21 @RheumNow https://t.co/PERx86jjkJ https://t.co/oEpbMZ0nnK

• https://bit.ly/3mY5kpf

Congrats to Dr. Debaditya Roy, Dr. Chinenye Osuorji and Dr. Vaneet Sandhu on the leaderboard for engaged learning during #ACR21 @rheumnow My points are pathetic compared to theirs and the top 10 https://t.co/yYppc029DM

#ACR21 Ab#L03: B cell depletors and #COVID19 vax: ⭐️B cell count <40 around vax had lower response to vax, than 40+ B-cell, independent of RTX or BEL ▶️ Timing of vax around B cell return can improve response @Rheumnow https://t.co/1B7Bnb1QQu https://t.co/bKnfw6gD8O

• https://bit.ly/3qjnNij